ABSTRACT
Investigate whether disparities and other factors influence referral to genetic counseling and testing for hereditary breast and ovarian cancer syndrome (HBOC) in a large health care system. Examination of clinical, demographic, and socioeconomic factors from electronic health records associated with genetic referral and testing within 12 months after a new cancer diagnosed between August 1, 2013 and December 31, 2018. For patients meeting institutional criteria for HBOC testing, 60.6% were referred for genetic counseling, 88% of whom underwent germline testing; at least one pathogenic variant was found in 15.3%. Referral rates for patients with breast (69%) or ovarian cancer (65.7%) were much higher than for metastatic prostate (11.1%, p < 0.0001) or pancreatic cancer (22.3%, p < 0.0001); referral criteria were implemented more recently for the latter two cancers. Younger age, family history, and chemotherapy were associated with referral. Higher Elixhauser comorbidity score and prior cancer were associated with non-referral. No other factors were associated with genetic referral for all eligible cancers combined, although differences were seen in specific cancers. Race was a significant factor only for breast cancer, with fewer Asians than Whites referred. Health disparities in referral to genetics for HBOC cancers are mitigated in a comprehensive integrated health care system.
Subject(s)
Breast Neoplasms , Hereditary Breast and Ovarian Cancer Syndrome , Ovarian Neoplasms , Breast Neoplasms/diagnosis , Breast Neoplasms/epidemiology , Breast Neoplasms/genetics , Delivery of Health Care , Female , Genetic Counseling/psychology , Genetic Predisposition to Disease , Genetic Testing , Hereditary Breast and Ovarian Cancer Syndrome/diagnosis , Hereditary Breast and Ovarian Cancer Syndrome/epidemiology , Hereditary Breast and Ovarian Cancer Syndrome/genetics , Humans , Male , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/epidemiology , Ovarian Neoplasms/geneticsABSTRACT
PURPOSE: To describe breast and ovarian cancer risk reduction strategies in the clinical management of women who test positive for non-BRCA hereditary breast and ovarian cancer (HBOC) pathogenic variants compared to those who test positive for pathogenic BRCA variants or have negative germline panel testing. METHODS: Examination of imaging and preventive surgeries in women undergoing HBOC genetic testing from 1/1/2015 to 12/31/2018, with follow up to 03/31/2020 in Kaiser Permanente Northern California. RESULTS: A total of 13,271 tests which included HBOC genes were identified. Rate of bilateral salpingo-oophorectomy after genetic testing were similar for BRCA and the non-BRCA moderate risk ovarian pathogenic variants (PVs) (47.4% vs 54%, p = 0.25). Rates were lower for low risk or unknownrisk non-BRCA PVs (12.8%, p < 0.001, 5.3% (p < 0.001). Rates of surveillance for ovarian cancer with ultrasound and CA 125 in the first year was 63.3% and 64.7% for BRCA PV, 37.5% and 27.1%, for non-BRCA moderate risk PVs and 13.7% and 4.6%, for low-risk PVs. Bilateral mastectomy rates were 19.7% for BRCA PV, 10.1% (p = 0.028) for non-BRCA breast high risk PVs, for moderate risk PVs 7.7% (p < 0.001) and for unknown risk 0.4% (p < 0.001). MRI surveillance rates in the first year similarly were 47.4% for non-BRCA BRCA PV, 43% for breast high risk PV, 39.4% for moderate risk and 4.9% for unknown risk PV. CONCLUSION: Surgical and surveillance strategies are underutilized for HBOC PV, however there is concordance of uptake of preventive strategies with specific risk associated with non-BRCA PVs.
Subject(s)
Breast Neoplasms , Ovarian Neoplasms , Female , Humans , Breast Neoplasms/genetics , Breast Neoplasms/surgery , Breast Neoplasms/diagnosis , Mastectomy , Ovarian Neoplasms/genetics , Ovarian Neoplasms/prevention & control , Ovarian Neoplasms/surgery , Delivery of Health Care , Genetic Predisposition to DiseaseABSTRACT
OBJECTIVE: Referral to Genetics for pre-testing counseling may be inefficient for women with ovarian cancer. This study assesses feasibility of gynecologic oncologists directly offering genetic testing. METHODS: A prospective pilot study was conducted at two gynecologic oncology hubs in an integrated healthcare system from May 1 to November 6, 2019. Gynecologic oncologists offered multigene panel testing to women with newly diagnosed ovarian cancer, followed by selective genetic counseling. Outcomes were compared between study participants and women from other hubs in the health system. RESULTS: Of ovarian cancer patients at study sites, 40 participated and all underwent genetic testing. Of 101 patients diagnosed at other sites, 85% were referred to genetics (p = .0061 compared to pilot participants) and 67% completed testing (p < .0001). The time from diagnosis to blood draw and notification of result was 18.5 and 34 days for the pilot group compared to 25.5 and 53 days at other sites. Panel testing detected 9 (22.5%) and 7 (10.3%, p = .08) pathogenic mutations in each group, respectively. Patients and providers were highly satisfied with the streamlined process. CONCLUSION: Genetic testing performed at the gynecologic oncology point of care for patients with ovarian cancer is feasible, increases uptake of testing, and improves time to results.
Subject(s)
Delivery of Health Care, Integrated/organization & administration , Genetic Testing/methods , Ovarian Neoplasms/diagnosis , Point-of-Care Testing/organization & administration , Aged , California , Carcinoma, Ovarian Epithelial , Delivery of Health Care, Integrated/statistics & numerical data , Feasibility Studies , Female , Genetic Counseling/statistics & numerical data , Genetic Predisposition to Disease , Genetic Testing/statistics & numerical data , Gynecology/methods , Gynecology/organization & administration , Health Plan Implementation , Humans , Medical Oncology/methods , Medical Oncology/organization & administration , Middle Aged , Ovarian Neoplasms/genetics , Patient Acceptance of Health Care/statistics & numerical data , Patient Satisfaction , Pilot Projects , Point-of-Care Testing/statistics & numerical data , Program Evaluation , Prospective Studies , Referral and Consultation/statistics & numerical data , Time FactorsABSTRACT
OBJECTIVE: Describe clinical characteristics and risk reducing strategies utilized among women with a BRCA mutation who lived to age 75 and above. METHODS: A retrospective study of women with BRCA mutations identified from 1995 to 2015 in a California health care system. From a database of 1189 women, 69 participants were identified who lived to age 75 or older. Demographic and clinical characteristics were recorded, as well as cancer history and risk-reducing strategies utilized. Descriptive and bivariate analyses were used to analyze the cohort. RESULTS: The median age of the cohort at study entry was 78 (IQR: 76-84) and the median age at time of genetic testing was 73 (IQR 68-79). Fifty (72%) women had a prior history of breast cancer and 27 (39%) had a history of ovarian cancer. Three of 19 (16%) women with no history of breast cancer elected to undergo a risk-reducing mastectomy (RRM) after their positive genetic test. Among 30 women with ovaries still in place, 14 (47%) underwent a risk-reducing salpingo-oophorectomy (RRSO); six were age 70 or older at the time of surgery. Four (6%) women in the cohort developed BRCA-related cancer after testing, one developed breast cancer and three developed pancreatic cancer. CONCLUSIONS: Most women with BRCA mutations surviving beyond age 75 received their genetic test result at an older age and had a history of BRCA-related cancer. Women continued surveillance and risk reducing surgeries at an older age. Pancreatic cancer was the most common new cancer diagnosed in older BRCA mutation carriers.
Subject(s)
BRCA1 Protein/genetics , BRCA2 Protein/genetics , Breast Neoplasms/genetics , Genetic Testing/statistics & numerical data , Ovarian Neoplasms/genetics , Age Distribution , Aged , Aged, 80 and over , Breast Neoplasms/epidemiology , Breast Neoplasms/prevention & control , Female , Humans , Mastectomy , Mutation , Ovarian Neoplasms/epidemiology , Ovarian Neoplasms/prevention & control , Ovariectomy , Retrospective StudiesABSTRACT
OBJECTIVE: Exome sequencing is a successful option for diagnosing individuals with previously uncharacterized genetic conditions, however little has been reported regarding its utility in a prenatal setting. The goal of this study is to describe the results from a cohort of fetuses for which exome sequencing was performed. METHODS: We performed a retrospective analysis of the first seven cases referred to our laboratory for exome sequencing following fetal demise or termination of pregnancy. All seven pregnancies had multiple congenital anomalies identified by level II ultrasound. Exome sequencing was performed on trios using cultured amniocytes or products of conception from the affected fetuses. RESULTS: Relevant alterations were identified in more than half of the cases (4/7). Three of the four were categorized as 'positive' results, and one of the four was categorized as a 'likely positive' result. The provided diagnoses included osteogenesis imperfecta II (COL1A2), glycogen storage disease IV (GBE1), oral-facial-digital syndrome 1 (OFD1), and RAPSN-associated fetal akinesia deformation sequence. CONCLUSION: This data suggests that exome sequencing is likely to be a valuable diagnostic testing option for pregnancies with multiple congenital anomalies detected by prenatal ultrasound; however, additional studies with larger cohorts of affected pregnancies are necessary to confirm these findings.
Subject(s)
Abnormalities, Multiple/genetics , Congenital Abnormalities/genetics , Exome/genetics , Osteogenesis Imperfecta/genetics , Abnormalities, Multiple/diagnostic imaging , Abortion, Induced , Arthrogryposis/diagnostic imaging , Arthrogryposis/genetics , Collagen Type I/genetics , Congenital Abnormalities/diagnostic imaging , Female , Fetal Death , Genetic Testing , Glycogen Debranching Enzyme System/genetics , Glycogen Storage Disease Type IV/diagnostic imaging , Glycogen Storage Disease Type IV/genetics , Humans , Male , Mutation , Orofaciodigital Syndromes/diagnostic imaging , Orofaciodigital Syndromes/genetics , Osteogenesis Imperfecta/diagnostic imaging , Pregnancy , Proteins/genetics , Retrospective Studies , Sequence Analysis, DNA , Ultrasonography, PrenatalABSTRACT
Family history screening to identify individuals at increased risk for hereditary cancers could be a powerful strategy to prevent cancer but is used inconsistently in primary care. The objective was to improve identification of women with at-risk family histories using a point-of-care family history screening tool administered on an electronic tablet device during well-woman appointments. A total of 288 women were invited to participate and 136 women (47.2%) completed the electronic family history screening tool. Significantly more women were identified and referred to the genetics department with the electronic family history screening tool than the standard-of-care paper questionnaire (11.8% versus 0.8%, P < 0.001). There were no statistically significant differences in the proportion of referred women who were evaluated by the genetic counselors, and no pathogenic variants were found with either family history screening method. Implementing innovative self-reporting tools may improve inherited cancer risk detection.
Subject(s)
Early Detection of Cancer , Neoplasms , Electronics , Female , Humans , Neoplasms/diagnosis , Neoplasms/genetics , Pilot Projects , Prospective StudiesABSTRACT
OBJECTIVES: To identify the decision-making factors and personal characteristics of women who opt for and against amniocentesis following a screen-positive maternal serum screen (MSS) result. METHODS: A questionnaire was mailed to 597 women who were randomly selected among women in the province of British Columbia (BC) who screened positive for Down syndrome (DS) on the MSS between January and June 2005. Subjects were evenly distributed across two main parameters: screen-positive women who opted for, and declined, amniocentesis (Groups 1 and 2, respectively). RESULTS: Significant differences (P < 0.05) between Groups 1 and 2 include; reasons for wanting the MSS, post-positive MSS anxiety level, risk of miscarriage associated with amniocentesis, MSS risk estimate, reasons for wanting, or not wanting amniocentesis, normal fetal ultrasound, attitudes towards termination and religious beliefs. About half of all women across both groups did not find the MSS helpful in their pregnancy, primarily stating that it caused unnecessary increased anxiety. CONCLUSIONS: To help avoid, or at least prepare women for the likelihood of increased anxiety following a screen-positive MSS result, and help prepare them for decision making, it is important to target MSS counselling to the individuality of the patient, and address these factors before MSS is undertaken.
Subject(s)
Amniocentesis/psychology , Decision Making/physiology , Down Syndrome/diagnosis , Hematologic Tests , Mothers , Abortion, Spontaneous/etiology , Abortion, Spontaneous/psychology , Adult , Amniocentesis/adverse effects , Anxiety/epidemiology , Down Syndrome/blood , Down Syndrome/psychology , Female , Genetic Counseling , Humans , Mothers/psychology , Pregnancy , Prenatal Diagnosis/adverse effects , Prenatal Diagnosis/psychology , Risk Factors , Surveys and QuestionnairesABSTRACT
Constitutional SMARCB1 mutations at 22q11.23 have been found in â¼50% of familial and <10% of sporadic schwannomatosis cases. We sequenced highly conserved regions along 22q from eight individuals with schwannomatosis whose schwannomas involved somatic loss of one copy of 22q, encompassing SMARCB1 and NF2, with a different somatic mutation of the other NF2 allele in every schwannoma but no mutation of the remaining SMARCB1 allele in blood and tumor samples. LZTR1 germline mutations were identified in seven of the eight cases. LZTR1 sequencing in 12 further cases with the same molecular signature identified 9 additional germline mutations. Loss of heterozygosity with retention of an LZTR1 mutation was present in all 25 schwannomas studied. Mutations segregated with disease in all available affected first-degree relatives, although four asymptomatic parents also carried an LZTR1 mutation. Our findings identify LZTR1 as a gene predisposing to an autosomal dominant inherited disorder of multiple schwannomas in â¼80% of 22q-related schwannomatosis cases lacking mutation in SMARCB1.
Subject(s)
Chromosomes, Human, Pair 22/genetics , Genetic Predisposition to Disease/genetics , Germ-Line Mutation/genetics , Models, Molecular , Neurilemmoma/genetics , Protein Conformation , Transcription Factors/genetics , Base Sequence , Chromosomal Proteins, Non-Histone/genetics , DNA, Complementary/genetics , DNA-Binding Proteins/genetics , Gene Components , Genes, Dominant/genetics , Humans , Loss of Heterozygosity , Microsatellite Repeats/genetics , Molecular Sequence Data , Neurofibromatosis 2/genetics , Pedigree , SMARCB1 Protein , Sequence Analysis, DNA , Transcription Factors/chemistryABSTRACT
BACKGROUND: Arteriosclerosis and emphysema develop in individuals with Schimke immuno-osseous dysplasia (SIOD), a multisystem disorder caused by biallelic mutations in SMARCAL1 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like 1). However, the mechanism by which the vascular and pulmonary disease arises in SIOD remains unknown. METHODS: We reviewed the records of 65 patients with SMARCAL1 mutations. Molecular and immunohistochemical analyses were conducted on autopsy tissue from 4 SIOD patients. RESULTS: Thirty-two of 63 patients had signs of arteriosclerosis and 3 of 51 had signs of emphysema. The arteriosclerosis was characterized by intimal and medial hyperplasia, smooth muscle cell hyperplasia and fragmented and disorganized elastin fibers, and the pulmonary disease was characterized by panlobular enlargement of air spaces. Consistent with a cell autonomous disorder, SMARCAL1 was expressed in arterial and lung tissue, and both the aorta and lung of SIOD patients had reduced expression of elastin and alterations in the expression of regulators of elastin gene expression. CONCLUSIONS: This first comprehensive study of the vascular and pulmonary complications of SIOD shows that these commonly cause morbidity and mortality and might arise from impaired elastogenesis. Additionally, the effect of SMARCAL1 deficiency on elastin expression provides a model for understanding other features of SIOD.
Subject(s)
Arteriosclerosis/physiopathology , Emphysema/physiopathology , Immunologic Deficiency Syndromes/physiopathology , Nephrotic Syndrome/physiopathology , Osteochondrodysplasias/physiopathology , Pulmonary Embolism/physiopathology , Adult , Arteriosclerosis/genetics , Autopsy , Child , Child, Preschool , DNA Helicases/genetics , Emphysema/genetics , Female , Humans , Immunohistochemistry , Immunologic Deficiency Syndromes/genetics , Male , Nephrotic Syndrome/genetics , Osteochondrodysplasias/genetics , Primary Immunodeficiency Diseases , Pulmonary Embolism/geneticsABSTRACT
Various models of cancer genetics service delivery have been published, and practice guidelines were set forth by the National Society of Genetic Counselors (NSGC) in 2004. While the demand for services has increased, there has not been a comprehensive study of current practice models. An online survey of the NSGC Familial Cancer Risk Counseling Special Interest Group was conducted to study current methods of providing clinical cancer genetics services. Respondents were asked to quantify patient volume, support staff availability, and physician involvement in cases. Two case examples were used to further describe current practices including the number of genetic counseling tasks performed, time spent in these tasks, and number of in-person visits versus phone encounters. Although published cancer genetic counseling guidelines advise a 3-visit model (initial consult, sample draw, and result disclosure), 29.3% of respondents have adopted a 1-visit model, where the sample is drawn at the first visit and phone disclosure replaces the third visit. The content of the initial consult does not vary significantly, and is consistent with the NSGC practice guidelines. Furthermore, 56% report spending >15 min on case preparation, and 27 respondents self-reported redundancy in tasks such as documentation. It appears that a proportion of genetic counselors are following a new model of service delivery. However, insufficient documentation and case preparation are apparent, and many respondents reported lack of support staff as a barrier to efficient patient care. Factors contributing to the variability in current practice, and how they affect efficiency, require further study.